Genetic precision nutrition as medicine
With genetic knowledge, molecular nutritional principles can be applied to pinpoint the root cause of disease …
SAN DIEGO (PRWEB)
May 20, 2021
GB HealthWatch, a pioneer in translational genomics, announces the launch of its GBinsight Nutritional Genomics comprehensive panel for genetic testing and analysis as a core component of its preventive health care platform. Adding nutritional genomics to the company’s extensive Next Generation Sequencing (NGS) -based genetic testing catalog was a strategic move for GB HealthWatch to break into the genetics-based, precision preventive healthcare space.
Common cardiometabolic disorders such as dyslipidemia, coronary artery disease, obesity, and type 2 diabetes are largely preventable. With genetic insights, molecular nutritional principles can be applied to precisely address the causes of these diseases and employ targeted and personalized diet and lifestyle interventions. By integrating genetic data into the HealthWatch 360 app, a secure and HIPAA-compliant nutritional therapy mobile application also developed by GB HealthWatch, the company aims to provide doctors, patients and the public with accurate dietary recommendations and precise preventative health products and services Digital technology.
As the era of precision health begins, we will increasingly use genetic information to identify health risks and develop prevention strategies to avoid or delay disease outbreaks. A strategic goal of nutritional genomics is to match preventive and therapeutic nutrition and nutritional recommendations to a person’s genetic makeup. “Diet and lifestyle changes have been shown to be particularly effective in preventing and reducing the severity of many cardiometabolic disorders,” said Christina Troutner, MS, RDN, a registered nutritionist and nutritionist with GB HealthWatch. “Nutritional genomics enables us to identify precise nutritional mechanisms for combating diseases, which can then be converted into personalized nutritional recommendations. In this way, food becomes medicine. “
“The pathophysiological processes that underlie cardiometabolic disease begin decades before the onset of symptoms,” said Dr. Mendel Roth, PhD, senior scientist at GB HealthWatch. “Knowing your genetics can help identify the specific root cause of a disease and provide an opportunity to tailor you to the most effective prevention and treatment regimes.”
GBinsight’s nutritional genomics genetic testing is focused on the detection of diet modifiable genetic risk factors often associated with hypercholesterolemia, hypertriglyceridemia, non-alcoholic fatty liver disease, type 2 diabetes, and obesity. The analysis of some traits that affect individual nutritional needs and preferences, as well as food intolerances and sensitivities, is also included. Each GBinsight Nutritional Genomics Report provides the clinician and patient with personalized nutritional and nutritional recommendations that follow the guidelines of professional organizations such as the National Lipid Association (NLA), the American Heart Association / American College of Cardiology (AHA / ACC), and the American Diabetes Associations conform (ADA). In addition, linking personal genetic data to the HealthWatch 360 app promotes patient loyalty by giving patients the ability to view digital versions of their genetic test reports, browse relevant information about genetic nutrition and disease education, and monitor dietary quality and lifestyle changes on their own .
The GBinsight Nutritional Genomics Comprehensive Panel analyzes the following conditions and makes genetics-based dietary recommendations:
- Hypercholesterolemia
- Hypertriglyceridemia
- hypertension
- Alcohol-free fatty liver disease (NAFLD)
- obesity
- Type 2 diabetes
An analysis for nutrient deficiencies as well as food intolerances and sensitivities is also included:
- Gluten intolerance
- Fat intolerance
- Lactose intolerance
- Iron overload
- Folate deficiency
- Vitamin B12 deficiency
- Omega-3 fatty acid deficiency
- Caffeine sensitivity
The ability to use molecular nutritional principles to combat today’s diseases cannot be underestimated. Beneficial diet and lifestyle interventions have been shown to be significantly effective as conjunctive treatments for high cholesterol and triglycerides, hypertension, heart disease, type 2 diabetes, and weight gain. If genetic testing can pinpoint and target the exact genetic culprit, personalized intervention schemes could be the most effective and effective way to redirect the course of metabolic disease and improve patient outcomes. For example, genetic loss of function of lipoprotein lipase (LPL) or related proteins impairs the ability to remove dietary fat from the bloodstream, which can manifest as severe hypertriglyceridemia from consuming a high-fat or simple high-carbohydrate (high-sugar) diet. By restricting dietary fat intake, limiting sugary foods, and adding fat-soluble vitamins, blood triglycerides can be reduced along with the associated risks for heart disease and type 2 diabetes. In addition, genetic analysis and genetic-based risk assessments have been shown to empower and motivate patients to adopt healthy lifestyle changes.
In contrast to other DTC genetic testing companies (direct-to-consumer) who rely on outdated microarray technologies, GBinsight uses NGS, with the novel and rare variants, insertions / deletions, multi-nucleotide variants (MNV) and variations in the number of copies can be proven. Current studies confirm that microarray technologies are not suitable for the detection of rare and realizable genetic variants and can only analyze a fixed number of single nucleotide polymorphisms (SNPs). In contrast, GBinsight’s platform can identify genetic variants that microarray technology simply cannot, while providing more precise and relevant diet and nutrition recommendations for disease control. In fact, research has shown that around 40% of the variants of the various genes reported in the DTC raw data were false positive and therefore can mislead consumers as to the actual risk of disease.
GBinsight is a comprehensive and targeted NGS assay for analyzing the genetic architecture of complex diseases. Combined with a novel, cutting-edge bioinformatics analysis algorithm, GBinsight genetic testing and analysis promises to help scientists and clinicians gain genetic insight into common metabolic diseases and facilitate research into personalized prevention and medical intervention strategies. GBinsight is a simple and inexpensive solution to study the genetic basis of a disease and develop targeted therapies based on knowledge of the underlying biology. GBinsight NGS services are performed in a CLIA certified and medically licensed genetic testing laboratory using Illumina’s HiSeq platform.
The GBinsight test catalog contains the following:
- Comprehensive panel for dyslipidemia
- Familial Hypercholesterolemia Panel
- Familial Hypertriglyceridemia Panel
- Comprehensive panel on coronary heart disease
- Type 2 Diabetes Comprehensive Panel
- Diabetes MODY panel
- Comprehensive panel on obesity
- Panel on nonsyndromic monogenic obesity
- Comprehensive panel on nutritional genomics
Via GB HealthWatch
GB HealthWatch is a nutritional genomics company. We develop state-of-the-art technologies to facilitate research into the molecular mechanisms, clinical efficacy and cost-effectiveness of translating genetic knowledge into personalized prevention and treatment strategies for complex diseases. GB HealthWatch offers the following products and services:
Visit the GB HealthWatch website to learn more.
About the Otogenetics Corporation
Otogenetics Corporation is a CLIA certified and licensed medical genetic testing company specializing in next generation sequencing services. Otogenetics provides high quality genome, exome and RNA sequence services to government and academic institutions, biotechnology and pharmaceutical companies, doctors and clinics. Additional services and products from Otogenetics Corporation can be found at: http://www.otogenetics.com.
Share articles on social media or via email:
